SCA Pharma Awarded National Outsourced I.V. Admixture Services Agreement with Premier

Windsor, Connecticut – January 3, 2019— SCA Pharma, an FDA approved 503B sterile-compounding organization, announced today that they have been awarded a group purchasing agreement for Outsourced I.V. Admixture Services with Premier Inc.

Beginning January 1, 2019, this new agreement allows Premier members, at their discretion, access to a wide range of outsourced pharmaceuticals. SCA features an extensive product catalog containing products in the following pharmaceutical categories:

Analgesics, Anesthetics, Antiarrhythmics, Antibiotics, Anticholinergics, Anticoagulants, Antihypertensive Drugs, Diuretics, Electrolytes, Neuromuscular Blockers, Opioid Analgesics, Oxytocic Agents, Reversal Agents and Vasopressors.

One of the nation’s leading healthcare improvement organizations, Premier Inc. unites an alliance of approximately 4,000 U.S. hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

Milton Boyer, Chief Executive Officer of SCA Pharma remarked “Quality, commitment, and service should be the driving force for every 503B. We are committed to our focuses on cGMP Quality standards and transparency.”

As the 503B space continues to evolve, SCA is poised and ready to meet the needs of an ever-changing industry. Mr. Boyer stated “The demand for reputable, high-quality 503B companies is on the rise. We see an opportunity to grow and meet the demands of medication shortages and compound medication with hospitals and GPOs that will further both medication and patient safety.

About SCA Pharma

SCA Pharma is an FDA 503B outsourcing facility providing the highest quality sterile admixtures and pre-filled syringes to meet the needs of patients. Licensed in all 50 states, SCA offers an extensive catalog, as well as outstanding quality and customer service. Since day one, SCA has performed 100% final product sterility testing with lot-specific lab reports for every sterile product produced. SCA additionally performs environmental monitoring, potency and full endotoxin testing on every batch of sterile products, prior to release, fulfilling requirements for Endotoxin (Pyrogen) testing per USP Guidelines and cGMP guidance.

For more information on SCA Pharma, visit www.scapharma.com.

Media Contact

Brenden Roche

broche@scapharma.com

860-985-2689

Shannon Daley